#ASH24: First-line and emerging therapies for ALL

Stay up to date with the latest developments in first-line and emerging therapies for acute lymphoblastic leukemia from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition with our live social media coverage.

CONGRESS #ASH24 | PRESENTATION
Melissa A. Burns, @DanaFarber presented results from DFCI ALL Consortium Protocol 16-001. Only 4 patients on the reduced dose required increased dose adjustment. There was no difference in toxicities between the fixed and reduced dose pegaspargase… pic.twitter.com/ORAyb8ilkQ

— ALL Hub (@ALL_Hub_) December 8, 2024

CONGRESS #ASH24 | PRESENTATION
Daniel J. DeAngelo @DanaFarber discussed findings from the Alliance A041501 Phase 3. There were more Grade 5 events in the INO + chemotherapy arm (12) vs control, standard chemotherapy arm (3). 3-yr EFS was 69% in INO arm vs 67% in control arm.… pic.twitter.com/p4RIqDNGZJ

— ALL Hub (@ALL_Hub_) December 8, 2024

CONGRESS #ASH24 | PRESENTATION
Martin Schrappe, Clinical Research Unit CATCH ALL, presented results from the Phase 3 Trial AIEOP-BFM ALL 2009. Reducing anthycycline in induction was safe and did not increase relapse risk. Toxcitiy was higher with 4 doses of DNR vs 2 doses. Follow… pic.twitter.com/mtzGqUhI3l

— ALL Hub (@ALL_Hub_) December 8, 2024

CONGRESS | #ASH24 | Ashley Pinchinat @nyulangone discusses the prognostic impact of t(1;19) in pediatric B-ALL treated with contemporary COG protocols; concluding that t(1;19) alone was not associated with inferior outcomes and do not require therapy intensification based on… pic.twitter.com/H96xxyuTQr

— ALL Hub (@ALL_Hub_) December 8, 2024

CONGRESS #ASH24 | PRESENTATION
Rachel E. Rau, @seattlechildren discussed results from the AALL1731 study of blinatumomab added to chemo in children with NCI SR B-ALL. Blinatumomab reduced the risk of marrow involving relapses, but not isolated CNS relapses, and led to increased… pic.twitter.com/ZkbR7sZnMa

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS | #ASH24 | POSTER
Fausto A Rios-Olais @faustor @incmnszmx shares findings from a study examining the relationship between metabolic complications and asparaginase-containing pediatric-inspired regimens in adult patients with ALL (N = 92).
Liver steatosis was associated… pic.twitter.com/RzcgZZxea3

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS | #ASH24 | POSTER
Erlie Jiang from the Chinese Academy of Medical Sciences shares real-world data for dose-adjusted InO in adult patients with newly diagnosed (n=12), MRD-positive (n=19) or R/R (n=13) B-ALL. Dose-adjusted InO was a well-tolerated and effective treatment… pic.twitter.com/ubPaF1WfKR

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS | #ASH24 | PRESENTATION
Lennart Lenk @kieluni @UKSH_KI_HL presents results from a preclinical study of lusvertikimab for the treatment of ABL-class-fusion+ BCP-ALL.
Lusvertikimab plus imatinib treatment led to reduced PB blasts and survival prolongation vs control in… pic.twitter.com/kHVHzJyUtz

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS #ASH24 | PRESENTATION
Roberta Santos Azevedo, @MDAndersonNews discussed older age and TP53 mutations as predictors of myeloid neoplasm. Incidence of t-MN was highest in pts older than 60, and also higher with treatment intensity and TP53 mutation. t-MN risk was highest… pic.twitter.com/cI61Sttody

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS #ASH24 | PRESENTATION
Martin Schrappe, University Medical Center Schleswig-Holstein discussed results from the AIEOP-BFM ALL 2009 trial of pediatric pts with T-ALL. EOC-MRD is the strongest prognostic factor, PPR is a risk factor and CNS3 disease is a novel HR factor for… pic.twitter.com/qngHOLktNH

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS #ASH24 | PRESENTATION@WNMacaron, @MDAndersonNews and @bcmhouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1.… pic.twitter.com/OkcflAxNa2

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS #ASH24 | PRESENTATION@NicBoissel, @HopSaintLouis discussed CNS relapse in Ph- ALL. Male pts, and high WBC count increased risk of CNS relapse. EOI-MRD was associated with decreased risk on CNS relapse. CNS irradiation and TBI-based HSCT also decreased risk of CNS… pic.twitter.com/km18EiOivV

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS #ASH24 | PRESENTATION
Michaela Liedtke, @StanfordMed presented results from theECOG-ACRIN E1910 Phase III trial, investigating ASCT outcomes in B-ALL. OS was higher in pts treated with Blin+chemo vs chemo alone (82% vs 71% in MRD neg pts). In MRD neg pts on Blin + chemo,… pic.twitter.com/29OK7lVzF6

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS #ASH24 | PRESENTATION
Sabina Chiaretti, @SapienzaRoma discussed intermediate analysis of the Gimema ALL2820 study. In pts treated with ponatinib + blinatumomab, after a median follow-up of 8.5 months, estimated 12 month OS was 94.9%. 57 SAEs occured accross 40 pts.… pic.twitter.com/n78DgyMGic

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS #ASH24 | PRESENTATION
Shanshan Suo, Zhejiang University School of Medicine, presented results from a phase II trial of venetoclax combined with V-HAG regimen in ND ETP-ALL. 100% of pts achieved CR/CRi after 1 treatment cycle. Median OS was not reached, older age was… pic.twitter.com/v8bijXyJMk

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS #ASH24 | PRESENTATION
Nicholas J. Short, @MDAndersonNews discussed use of blinatumomab and ponatinib for ND Ph+ ALL. CR/CRi was achieved in 98% of pts, with 96% of pts achieving NGS MRD neg status. Estimated 3-yr OS was 88%. Follow our live feed for more updates:… pic.twitter.com/H0EIjXU7oe

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS #ASH24 | PRESENTATION
Jieping Lin, Southern Medical University presented results from a phase II trial of tucidinostat plus pediatric-inspired chemotherapy as 1st line therapy for ND ETP-ALL. CR/CRi rate was 91%. Median EFS was not reached, 3-yr EFS was 67.7% . After… pic.twitter.com/xOXN8AYbC7

— ALL Hub (@ALL_Hub_) December 10, 2024

CONGRESS #ASH24 | PRESENTATION
Heike Pfeifer, @goetheuni discussed an update on GMALL Trial 08/2013 of pts with Ph+ALL treated with imatinib, dose-reduced induction followed by SCT. OS at 5-yrs was 72%, with 5-yr durable remission of 89%. IKZF+ pts had a higher relapse rate.… pic.twitter.com/wl3yNWELP3

— ALL Hub (@ALL_Hub_) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Nicola Goekbuget @goetheuni shared results from the GMALL Trial 08/2013 which aims to address whether outcomes can be improved for MRD negative high-risk patients (aged 18-55) by avoiding SCT (n=93). The primary endpoint was not met, with no… pic.twitter.com/U1E132z1UV

— ALL Hub (@ALL_Hub_) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION@Anna_torrentC @CarrerasIJC shared preliminary results from the PETHEMA ALL19 trial evaluating outcomes in patients with Ph-ALL assigned to post-induction therapy according to genetic risk and MRD. Patients with MRD clearance and low genetic risk… pic.twitter.com/BFjJuJNfLJ

— ALL Hub (@ALL_Hub_) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Ibrahim Aldoss @cityofhope shared results a pilot study investigating CAR T-cell therapy in older patients (>55 years) with B-ALL in first remission. The use of CAR T-cell therapy was associated with low toxicity (no ICANS or ≥Grade 2 CRS).… pic.twitter.com/YyKQPwit02

— ALL Hub (@ALL_Hub_) December 10, 2024

CONGRESS | #ASH24 | POSTER
Marie Balsat from Lyon Sud Hospital Center shared findings the multicenter French-Belgian-Swiss GRAALL-2014 in which patients were considered for switching from E. coli-derived asparaginase (ASPA) to Erwinase asparaginase if they exhibited low activity,… pic.twitter.com/5iiJXWJwf6

— ALL Hub (@ALL_Hub_) December 10, 2024

CONGRESS | #ASH24 | POSTER
Jayastu Senapati @MDAndersonNews reported a chemotherapy minimized InO/Blina based treatment approach for frontline therapy in older patients with Ph- B-cell ALL. This chemotherapy-free approach appears tolerable and was associated with a 1-year PFS of… pic.twitter.com/DexLzZhNRW

— ALL Hub (@ALL_Hub_) December 11, 2024

CONGRESS | #ASH24 | POSTER
Daniel Nguyen @MDAndersonNews presented updated results from a phase II study investigating the addition of InO to hyper-CVAD plus blinatumomab in patients (aged 14-59) with newly diagnosed Ph- B-ALL. Early data indicate that addition of InO may improve… pic.twitter.com/YVJ23lrPIH

— ALL Hub (@ALL_Hub_) December 11, 2024

CONGRESS | #ASH24 | POSTER
Jayastu Senapati @MDAndersonNews reported the long-term safety and efficacy of InO +/- Blina added to a mini HCVD regimen as frontline therapy in older adults (≥60 yrs) with Ph- B-ALL. The mHCVD-InO +/- Blina regimen was tolerable with 5-year PFS and… pic.twitter.com/l1H1Bspdv8

— ALL Hub (@ALL_Hub_) December 11, 2024